230 related articles for article (PubMed ID: 37650213)
1. Assessment of women's treatment preferences for vasomotor symptoms due to menopause.
Shiozawa A; Thurston RC; Cook E; Yang H; King DD; Kristy RM; Mancuso S
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1117-1128. PubMed ID: 37650213
[TBL] [Abstract][Full Text] [Related]
2. Vasomotor symptom characteristics: are they risk factors for incident diabetes?
Gray KE; Katon JG; LeBlanc ES; Woods NF; Bastian LA; Reiber GE; Weitlauf JC; Nelson KM; LaCroix AZ
Menopause; 2018 May; 25(5):520-530. PubMed ID: 29206771
[TBL] [Abstract][Full Text] [Related]
3. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies.
Zhu D; Chung HF; Dobson AJ; Pandeya N; Anderson DJ; Kuh D; Hardy R; Brunner EJ; Avis NE; Gold EB; El Khoudary SR; Crawford SL; Mishra GD
Am J Obstet Gynecol; 2020 Dec; 223(6):898.e1-898.e16. PubMed ID: 32585222
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial.
Cohen LS; Joffe H; Guthrie KA; Ensrud KE; Freeman M; Carpenter JS; Learman LA; Newton KM; Reed SD; Manson JE; Sternfeld B; Caan B; Freeman EW; LaCroix AZ; Tinker LF; Booth-Laforce C; Larson JC; Anderson GL
Menopause; 2014 Apr; 21(4):347-54. PubMed ID: 23982113
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and impact of vasomotor symptoms due to menopause among women in Brazil, Canada, Mexico, and Nordic Europe: a cross-sectional survey.
Todorova L; Bonassi R; Guerrero Carreño FJ; Hirschberg AL; Yuksel N; Rea C; Scrine L; Kim JS
Menopause; 2023 Dec; 30(12):1179-1189. PubMed ID: 37847872
[TBL] [Abstract][Full Text] [Related]
6. Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network.
Joffe H; Guthrie KA; Larson J; Cohen LS; Carpenter JS; Lacroix AZ; Freeman EW
Menopause; 2013 Mar; 20(3):261-8. PubMed ID: 23435022
[TBL] [Abstract][Full Text] [Related]
7. Association between vasomotor symptom frequency and weight gain in the Study of Women's Health Across the Nation.
Gibson CJ; Shiozawa A; Epstein AJ; Han W; Mancuso S
Menopause; 2023 Jul; 30(7):709-716. PubMed ID: 37314873
[TBL] [Abstract][Full Text] [Related]
8. Vasomotor Symptoms and Accelerated Epigenetic Aging in the Women's Health Initiative (WHI).
Thurston RC; Carroll JE; Levine M; Chang Y; Crandall C; Manson JE; Pal L; Hou L; Shadyab AH; Horvath S
J Clin Endocrinol Metab; 2020 Apr; 105(4):1221-7. PubMed ID: 32080740
[TBL] [Abstract][Full Text] [Related]
9. A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women.
Blümel JE; Chedraui P; Baron G; Belzares E; Bencosme A; Calle A; Danckers L; Espinoza MT; Flores D; Gomez G; Hernandez-Bueno JA; Izaguirre H; Leon-Leon P; Lima S; Mezones-Holguin E; Monterrosa A; Mostajo D; Navarro D; Ojeda E; Onatra W; Royer M; Soto E; Tserotas K; Vallejo S;
Menopause; 2011 Jul; 18(7):778-85. PubMed ID: 21407137
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis.
Elnaga AAA; Alsaied MA; Elettreby AM; Ramadan A
Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():142-152. PubMed ID: 38640780
[TBL] [Abstract][Full Text] [Related]
11. Vasomotor symptoms and risk of cardiovascular disease in peri- and postmenopausal women: A systematic review and meta-analysis.
Armeni A; Anagnostis P; Armeni E; Mili N; Goulis D; Lambrinoudaki I
Maturitas; 2023 May; 171():13-20. PubMed ID: 36907116
[TBL] [Abstract][Full Text] [Related]
12. Identifying women who share patterns of reproductive hormones, vasomotor symptoms, and sleep maintenance problems across the menopause transition: group-based multi-trajectory modeling in the Study of Women's Health Across the Nation.
Matthews KA; Chang Y; Brooks MM; Crawford SL; Janssen I; Joffe H; Kravitz HM; Thurston RC; El Khoudary SR
Menopause; 2020 Oct; 28(2):126-134. PubMed ID: 33038144
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms.
Umland EM
J Manag Care Pharm; 2008 Apr; 14(3 Suppl):14-9. PubMed ID: 18439062
[TBL] [Abstract][Full Text] [Related]
14. Results of a pilot study of a cooling mattress pad to reduce vasomotor symptoms and improve sleep.
Avis NE; Levine BJ; Coeytaux R
Menopause; 2022 Aug; 29(8):973-978. PubMed ID: 35881974
[TBL] [Abstract][Full Text] [Related]
15. Beyond frequency: who is most bothered by vasomotor symptoms?
Thurston RC; Bromberger JT; Joffe H; Avis NE; Hess R; Crandall CJ; Chang Y; Green R; Matthews KA
Menopause; 2008; 15(5):841-7. PubMed ID: 18521049
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and quality-of-life burden of vasomotor symptoms associated with menopause: A European cross-sectional survey.
Nappi RE; Siddiqui E; Todorova L; Rea C; Gemmen E; Schultz NM
Maturitas; 2023 Jan; 167():66-74. PubMed ID: 36306669
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
Morga A; Ajmera M; Gao E; Patterson-Lomba O; Zhao A; Mancuso S; Siddiqui E; Kagan R
Menopause; 2024 Jan; 31(1):68-76. PubMed ID: 38016166
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States.
Stute P; Cano A; Thurston RC; Small M; Lee L; Scott M; Siddiqui E; Schultz NM
Maturitas; 2022 Oct; 164():38-45. PubMed ID: 35785563
[TBL] [Abstract][Full Text] [Related]
19. Vasomotor Symptoms and Quality of Life Among Veteran and Non-Veteran Postmenopausal Women.
Katon JG; Gray KE; Gerber MR; Harrington LB; Woods NF; Weitlauf JC; Bean-Mayberry B; Goldstein KM; Hunt JR; Katon WJ; Haskell SG; McCutcheon SJ; Gass ML; Gibson CJ; Zephyrin LC
Gerontologist; 2016 Feb; 56 Suppl 1():S40-53. PubMed ID: 26220418
[TBL] [Abstract][Full Text] [Related]
20. Duration of menopausal vasomotor symptoms over the menopause transition.
Avis NE; Crawford SL; Greendale G; Bromberger JT; Everson-Rose SA; Gold EB; Hess R; Joffe H; Kravitz HM; Tepper PG; Thurston RC;
JAMA Intern Med; 2015 Apr; 175(4):531-9. PubMed ID: 25686030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
